Last updated: Jun 27, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06050252 | 2 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery | PD-L1 -- immune checkpoint inhibitor + chemotherapy |
| NCT05727176 | 2 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | FGFR2 fusion -- irreversible FGFR inhibitor |
| NCT07670273 | 2 | Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer | HER2 -- antibody-drug conjugate (ADC); PD-L1 -- immune checkpoint inhibitor (anti-PD-L1 antibody); Multiple kinases -- multi-kinase inhibitor (TKI) |
| NCT07632235 | 1, 2 | A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | COX-2 -- selective inhibition (NSAID); PD-1 -- immune checkpoint blockade (monoclonal antibody) |
| NCT05568680 | 1 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Mesothelin -- KIR-CAR T cell therapy (SynKIR-110) |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 12 |
| Tianjin Medical University Cancer Institute and Hospital | 7 |
| Shanghai Zhongshan Hospital | 7 |
| Peking Union Medical College Hospital | 6 |
| AstraZeneca | 6 |
Countries/regions with the most active trial sites for cholangiocarcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Jul 1, 2026 | NCT07632235 | A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | COX-2 -- selective inhibition (NSAID); PD-1 -- immune checkpoint blockade (monoclonal antibody) |
| Jul 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
| May 2026 | NCT07614061 | Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer | CD160 -- autologous antigen-specific T-cell therapy |
| Mar 27, 2026 | NCT07107750 | Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer | IRAK4 -- small molecule inhibitor (Emavusertib) + chemotherapy (Gemcitabine, Cisplatin) + PD-L1 -- immune checkpoint inhibitor (Durvalumab) |
| Mar 2, 2026 | NCT07641036 | Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer | HER2 + CEACAM5 -- dual-target chimeric antigen receptor natural killer cells (CAR-NK) |
| Jan 30, 2026 | NCT07392541 | Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer | PD-L1 -- immune checkpoint inhibitor + chemotherapy + statin |
| Nov 4, 2025 | NCT07291947 | PULSAR Combined With Immunotherapy and Chemotherapy | PD-1 + CTLA-4 -- dual immune checkpoint inhibitors + radiation therapy (PULSAR) |
| Oct 22, 2025 | NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Fibroblast activation protein (FAP) -- monoclonal antibody |
You've seen the cholangiocarcinoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.